EUVIMEDEUVIMED entdecken
Crossref

Designing poly(gamma-aminobutyric acid)-based nanoparticles for the treatment of major depressive disorders

Bui Duc Tri, Babita Shashni, Hirofumi Matsui, Yukio Nagasaki

Journal of Controlled Release · 2023-08 · 360 · 110-121

DOI: 10.1016/j.jconrel.2023.06.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-08. Verfasst von Bui Duc Tri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Degree Program in Pure and Applied Sciences, Graduate School of Science and Technology, University of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-…. Hauptthemen laut MEDLINE: Major Depressive Disorder. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder (MDD) is a worldwide concern owing to its negative impact on the quality of life. Gamma-aminobutyric acid (GABA), an essential neurotransmitter in the brain, is important for regulating the enteric nervous system and gut-brain dual communication (gut-brain axis), thus providing gastrointestinal GABA and GABA-related pathways with possible targets for MDD treatment. However, the use of GABA for this disease remains limited due to its poor pharmacokinetic properties, including the low permeability through the blood-brain barrier, and the rapid clearance from the gastrointestinal tract. Since poly(amino acid)s are advantageous for improving the beneficial bioactivities of conventional amino acids, poly(gamma-aminobutyric acid) (poly(GABA)) is a potential candidate for MDD therapy. Nevertheless, the non-water-soluble and non-dispersible characteristics of poly(GABA) render difficulty in administering its conventional forms in vitro/in vivo, thereby hindering its therapeutic applications. Therefore, this study proposes a new design for poly(GABA) in nanoparticle form, which is composed of the amphiphilic diblock copolymers of poly(GABA) and poly(ethylene glycol), providing a suitable formulation for medication applications. Herein, we report on a new orally deliverable poly(GABA)-based nanoparticles (NanoGABA) in aqueous media and their efficacy on mouse depression models. NanoGABA treatment efficiently attenuated depression-like symptoms as evidenced by behavioral tests (forced swimming tests and tail suspension tests) and stress biomarkers (corticosterone). These findings suggest that the newly designed poly(GABA)-based nanoparticles are a promising candidate for the treatment of depression. STATEMENT OF SIGNIFICANCE: This research is the first to report the preparation of poly(GABA)-based nanoparticles in aqueous conditions with beneficial physical properties to open the gate for medical and pharmaceutical applications of poly (GABA). It is also a pioneer in using poly(GABA)-based materials for major depressive disorder therapeutics in vivo. Oral administration of NanoGABA attenuates depressive-like symptoms by targeting the enteric nervous system possibly through modulation of the gut-brain axis pathways with negligible toxicity, suggesting that NanoGABA is a promising therapeutic agent for major depressive disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderMiceAnimalsQuality of Lifegamma-Aminobutyric AcidBrainBlood-Brain Barrier

Stichwörter der Autor:innen

GABAGut-brain axisMajor depressive disorderNanoparticlePoly(GABA)

Substanzen

gamma-Aminobutyric Acid

Autor:innen und Institutionen

  • Degree Program in Pure and Applied Sciences, Graduate School of Science and Technology, University of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8573, Japan.
  • Department of Materials Science, Faculty of Pure and Applied Sciences, University of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8573, Japan.
  • Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Ibaraki 305-8575, Japan; Master's School of Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsuk…
  • Department of Materials Science, Faculty of Pure and Applied Sciences, University of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8573, Japan; Master's School of Medical Sciences, Graduate School of Comprehensive Huma…

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Tri, B. D., Shashni, B., Matsui, H., & Nagasaki, Y. (2023). Designing poly(gamma-aminobutyric acid)-based nanoparticles for the treatment of major depressive disorders. Journal of Controlled Release, 360, 110-121. https://doi.org/10.1016/j.jconrel.2023.06.021

Vancouver

Tri BD, Shashni B, Matsui H, Nagasaki Y. Designing poly(gamma-aminobutyric acid)-based nanoparticles for the treatment of major depressive disorders. Journal of Controlled Release. 2023;360:110-121. doi:10.1016/j.jconrel.2023.06.021

BibTeX
@article{Tri2023,
  author = {Tri, Bui Duc and Shashni, Babita and Matsui, Hirofumi and Nagasaki, Yukio},
  title = {Designing poly(gamma-aminobutyric acid)-based nanoparticles for the treatment of major depressive disorders},
  journal = {Journal of Controlled Release},
  year = {2023},
  volume = {360},
  pages = {110--121},
  doi = {10.1016/j.jconrel.2023.06.021}
}
Kostenlos starten →